Author Archives: webmaster

Cell Therapies Joins Innovative $60 Million Government Research Centre

September 10th, 2013 | Posted by webmaster in News - (Comments Off on Cell Therapies Joins Innovative $60 Million Government Research Centre)

Logo916L - No ACN




Cell Therapies Pty Ltd is an essential partner in a new $60 million Commonwealth Government project designed to help translate promising cellular therapy treatments from the lab bench to the marketplace. The Cooperative Research Centre for Cell Therapy Manufacturing is a $59 million, six-year project funded by $20 million in cash from the Federal Government and $39 million in cash and in-kind from 14 commercial and academic participants.

“Cell Therapies is extremely pleased to be named a key player in this unique collaboration. As one of the more mature companies operating in this space in Australia, we have taken part in many significant changes in the cellular therapies field for more than a decade and believe this CRC represents the next major development in this field,” said Ray Wood, CEO of Cell Therapies.

The rapidly evolving field of cell and tissue therapies has created as yet unmet demands on the materials and devices required for the efficient and safe processing of cells and tissue. By combining internationally recognised academic researchers with practicing clinicians and cell and tissue processors, this CRC intends to influence the speed and safety with which a new treatment paradigm can be introduced to standard of care medical practice.

A novel feature of this CRC is the inclusion of a “patient ready” manufacturing and regulatory compliance capability. Cell Therapies and ITEK Ventures Pty Ltd have formed a joint venture to manage the new manufacturing facilities at Mawson Lakes, South Australia.

By imbedding experienced regulatory and manufacturing skills in the mix of CRC resources the research outcomes can be migrated quickly into the clinic and routine practice.  Cell Therapies 12+ years of experience will be used to influence the R&D very early in the process. The aim is to capture value from a novel combination of surface scientists, academic researchers, clinicians and practitioners in the field of cell and tissue therapies. This CRC will be able to manufacture products that can be used in human trials. This ability to translate research into the clinic has attracted several international and a number of local participants to the CRC.

About Cell Therapies

Cell Therapies P/L is a contract manufacturing organisation (CMO) and cellular product distributor that both manufactures and deploys advanced cell based therapies. Cell Therapies P/L has become acknowledged as a leader and the most experienced cGMP compliant resource for cells and tissue in the Pan-Asian region. Working in close collaboration with its 51% shareholder, the Peter MacCallum Cancer Centre, Cell Therapies P/L manages the Center for Blood Cell Therapies (CBCT) through a comprehensive services agreement that permits it to provide its clients with one-stop-shop access to apheresis collection, cGMP compliant manufacturing, cryo-preservation, state of the art imaging (novel cell tracking).and clinical trial implementation.

Cell Therapies P/L manages three manufacturing licenses for Peter MacCallum Cancer Centre and a number of others for its clients.

For more information, contact Ray Wood at Cell Therapies on: 61 3 9656 1615 or via








Cell Therapies P/L joins CRC for Cell Therapy Manufacturing (CRC-CTM)

April 3rd, 2013 | Posted by webmaster in News - (Comments Off on Cell Therapies P/L joins CRC for Cell Therapy Manufacturing (CRC-CTM))

Cell Therapies P/L has become an essential partner in the recently approved Cooperative Research Center for Cell Therapies Manufacturing (CRC-CTM). The combination of world leading academic researchers with local and overseas commercial companies is a novel feature of the Australian Government sponsored CRC program.

The CRC-CTM’s research is directed towards improved manufacturing capabilities and lowered cost of goods (COGS). Targeted clinical indications include unresolved diabetic foot ulcers, Graft vs Host disease (GvHD) for transplant patients, type 2 diabetes and diseases of the immune system where T-cells are involved.

Cell Therapies P/L will provide the regulatory compliant environment that facilitates the migration of CRC-CTM research into the clinic. A feature of this CRC is the seamless integration of pure research with commercial scale reduction to practice via first in man and subsequent routine treatments.

New Chairman Appointed by Cell Therapies

January 28th, 2013 | Posted by webmaster in News - (Comments Off on New Chairman Appointed by Cell Therapies)

Cell Therapies Pty Ltd is pleased to announce that Dr Christian Behrenbruch has been appointed as Chairman of the Melbourne-based life sciences company. Dr Behrenbruch will also serve as a nominee non-executive director on behalf of the Peter MacCallum Cancer Centre, the major shareholder of Cell Therapies.

Dr Behrenbruch has a demonstrated track record of building successful organisations in the life sciences and healthcare arena. He is currently the Chief Executive Officer of ImaginAb, Inc. a venture-backed biotechnology company based in California and Singapore. Previous executive roles have included Managing Partner at Momentum Biosciences, Vice President at Siemens Healthcare, Sr. VP at CTI Molecular Imaging (sold to Siemens in a $1.1Bn transaction in 2005) and CEO of Mirada Solutions, a successful UK-based radiology company that was spun-out of the University of Oxford.

Dr Behrenbruch completed his undergraduate studies at Monash University, received a D.Phil (Ph.D) in biomedical engineering from Oxford University and an MBA jointly awarded by New York University and the London School of Economics. Dr Behrenbruch has also held several academic appointments, including a faculty position in the Department of Medical and Molecular Pharmacology at the University of California, Los Angeles. He is currently an adjunct professor and member of the Industry Advisory Board at RMIT University’s College of Business (Melbourne).

“We’re delighted with this appointment as Dr Behrenbruch brings a strong combination of academic excellence in healthcare, understanding of the regulatory challenges of product development and a proven track record as a ‘serial entrepreneur’ in financing and nurturing early-stage companies,” said Ray Wood, CEO of Cell Therapies.

“Cell Therapies has done a remarkable job of building a unique life sciences company with an unmatched track record in manufacturing and deploying complex products in the cell therapies space,” commented Dr. Behrenbruch. “The company has exciting growth potential in terms of new products and regional market opportunities as this ‘pillar’ of healthcare starts to yield technologies with significant therapeutic potential.”

For more information, contact Ray Wood at Cell Therapies on: 61 3 9656 1615 or /

Cell Therapies Gains Access to Innovative Cartilage Product

January 28th, 2013 | Posted by webmaster in News - (Comments Off on Cell Therapies Gains Access to Innovative Cartilage Product)

Cell Therapies has announced an exclusive licensing agreement with South Korean-based Medipost for the distribution and manufacture of its innovative product Cartistem® a cellular treatment for osteoarthritis (OA) and focal defects of the knee

CARTISTEM® is the world’s first therapeutic agent approved for treating degenerative arthritis and knee cartilage defects, which is based on stem cells derived from cord blood.

“CARTISTEM® is a treatment for an indication with an increasing frequency due to an aging population,” said Mr Ray Wood, CEO of Cell Therapies. “We believe this novel allogenic cell therapy can deliver relief to patients without an alternative.”

Since completion of Phase III trials and regulatory approval in Korea more than 450 patients have been successfully treated. A key finding of the Phase III trial was the positive outcome for older patients who have previously not been considered suitable for treatment.

For more information, contact Ray Wood at Cell Therapies on: 61 3 9656 1615 or via


January 29th, 2010 | Posted by webmaster in Uncategorized - (Comments Off on NEWLY DEVELOPED NANOPARTICLES FOR CELL TRACKING)

Giovanni Mandarano, Jyoti Arora, Dominic Wall, Simon Harrison, Noelene Bergen, Dodie Pouniotis and Peter Eu

The utilisation of magnetic resonance imaging (MRI) to noninvasively monitor cells using superparamagnetic iron oxide nanoparticles (SPIONs) as MRI contrast agents has been one of the major research focuses over the past several years. The ability to use MRI to image longitudinally offers an invaluable opportunity to track the migration, persistence and distribution of cell based therapeutics in vivo in humans.

Current approaches for cell labelling have focused on using commercial SPIONs with varying success. Therefore, there is a clinical need to develop SPIONs that are non-toxic, with appropriate size and high MRI contrast. We have utilised SPIONs with a silica coating to investigate the labelling ability and contrast enhancement of CD45+ and CD34+ expressing cells.

For more details, click here.